Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Novartis Pharmaceuticals
Novartis Pharmaceuticals
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
65 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Novartis Investigative Site
Edmonton, Alberta, Canada
Recruiting - Novartis Investigative Site
London, Ontario, Canada
Recruiting - Novartis Investigative Site
Toronto, Ontario, Canada
Recruiting - Novartis Investigative Site
Montreal, Quebec, Canada
Recruiting
- Novartis Investigative Site
Beijing, China
Recruiting - Novartis Investigative Site
Beijing, China
Recruiting - Novartis Investigative Site
Beijing, China
Recruiting - Novartis Investigative Site
Shanghai, China
Recruiting
- Novartis Investigative Site
Bron, France
Recruiting - Novartis Investigative Site
Clichy, France
Recruiting - Novartis Investigative Site
Montpellier, France
Recruiting - Novartis Investigative Site
Nantes, France
Recruiting - Novartis Investigative Site
Pessac, France
Recruiting - Novartis Investigative Site
Toulouse, France
Recruiting
- Novartis Investigative Site
Erlangen, Germany
Recruiting - Novartis Investigative Site
Essen, Germany
Recruiting - Novartis Investigative Site
München, Germany
Recruiting
- Novartis Investigative Site
Budapest, Hungary
Recruiting - Novartis Investigative Site
Szeged, Hungary
Recruiting
- Novartis Investigative Site
Cona, FE, Italy
Recruiting - Novartis Investigative Site
Genova, GE, Italy
Recruiting - Novartis Investigative Site
Milan, MI, Italy
Recruiting - Novartis Investigative Site
Rozzano, MI, Italy
Recruiting - Novartis Investigative Site
Pisa, PI, Italy
Recruiting - Novartis Investigative Site
Roma, RM, Italy
Recruiting - Novartis Investigative Site
Roma, RM, Italy
Recruiting - Novartis Investigative Site
Milan, Italy
Recruiting
- Novartis Investigative Site
Rotterdam, South Holland, Netherlands
Recruiting - Novartis Investigative Site
Utrecht, Netherlands
Recruiting
- Novartis Investigative Site
Gdansk, Poland
Recruiting - Novartis Investigative Site
Gliwice, Poland
Recruiting - Novartis Investigative Site
Krakow, Poland
Recruiting - Novartis Investigative Site
Poznan, Poland
Recruiting - Novartis Investigative Site
Warsaw, Poland
Recruiting - Novartis Investigative Site
Warsaw, Poland
Recruiting
- Novartis Investigative Site
Seoul, South Korea
Recruiting - Novartis Investigative Site
Seoul, South Korea
Recruiting - Novartis Investigative Site
Seoul, South Korea
Recruiting
- Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, Spain
Recruiting - Novartis Investigative Site
Oviedo, Principality of Asturias, Spain
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 May 2025
- Primary completion
- 8 Dec 2028
- Completion
- 23 Jan 2034
- Last update posted
- 30 Apr 2026
- Registered enrollment
- 240
- Registry id
- NCT06784752
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.